Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab beyond first progression in advanced non-squamous NSCLC
2010-022645-14Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Standard of care plus bevacizumab beyond progression with Standard of care alone (2 arms). Primary endpoint: Overall survival. Started Jan 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-022645-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022645-14.